^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF G466V + KIT K509Q

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1, KIT, KIT proto-oncogene receptor tyrosine kinase, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarc
    Entrez ID:
    673; 3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over4years
    [VIRTUAL] The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib (ESMO 2020)
    Legal entity responsible for the study: The authors. Funding: Has not received any funding.
    Clinical
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • GNAS (GNAS Complex Locus)
    |
    BRAF V600E • PIK3CA mutation • BRAF V600 • PIK3CA H1047R • IDH1 R132C • BRAF G466V • BRAF G466V + KIT K509Q • GNAS R201C • PIK3CA G1049R + AKT1 E17K • BRAF K601
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)